

PRESS RELEASE

PEGS Europe 2021: ProBioGen's Presentation shows how the DirectedLuck™ Transposase System streamlines Cell Line Development

Barcelona, Spain, November 3, 2021:

ProBioGen is pleased to share that today, its Chief Scientific Officer Dr. Volker Sandig has presented at 13th annual PEGS Europe, the Protein & Antibody Engineering Summit in Barcelona.

During his talk, Volker shared insights on the latest addition to ProBioGen's renowned CHO.RiGHT® cell line development platform, the [DirectedLuck Transposase](#) technology, and how it streamlines the generation of clones and cell lines producing complex multi-specific mAbs at outstanding titers while achieving highest rates of the desired form.

The DirectedLuck technology displays a transposase engineered for highest activity and equipped with an epigenetic reader domain. This way it inserts the mAbs expression units in highly active spots of the host cell's genome leading to great expression levels while maintaining genetic/phenotypic stability. With this foundation, the focus for screening producer clones is entirely on correct pairing and desired critical quality attributes (CQA) such as posttranslational modifications (PTMs).

Find out how this system is applicable to various formats removing a critical bottleneck during clinical development for the development of multi-specific mAbs.

If you did not have the chance to attend the talk, contact us at cmo@probiogen.de.

We are looking forward to get in touch with you.

About ProBioGen

[ProBioGen](#) is a premier, Berlin-based specialist for developing and manufacturing complex therapeutic glycoproteins.

Combining both state-of-the-art development services, based on ProBioGen's CHO.RiGHT expression and manufacturing platform, together with intelligent product-specific technologies yields biologics with optimized properties.

Rapid and integrated cell line and process development, comprehensive analytical development and following reliable GMP manufacturing is performed by a highly skilled and experienced team. All services and technologies are embedded in a total quality management system to assure compliance with international ISO and GMP standards (EMA/FDA).

ProBioGen has been operational for more than 25 years. At two locations in Berlin, more than 200 employees contribute to the creation of new therapies in medicine and groundbreaking innovations worldwide through their creative and meticulous work.

ProBioGen Contact:

Dr. Gabriele Schneider
Chief Business Officer
cmo@probiogen.de
+49 (0)30 3229 35 100
www.probiogen.de

ProBioGen Press Contact:

Sarah Wandrey
Corporate Communications
press@probiogen.de